fig4

Figure 4. Inclusion of rare exocrine tumor patients on clinical studies of pancreatic cancer. Study registrations on clinicaltrials.gov over the last two years (from 8/2020 through 8/2022) were searched for those that were interventional, enrolled adults, and included the term pancreas cancer, resulting in identification of 425 records. Eliminating those specific for PNET, carcinoid syndrome or endocrine tumors resulted in 405 entries. 267 of these were specific for pancreas cancer and did not include other tumor types. After exclusion of those evaluating screening regimens, diagnostic procedures (imaging, molecular profiling), interventional procedures (endoscopy, surgery, anesthesia), and psychological, dietary, or lifestyle modification, 214 studies testing medical interventions were identified. The percentage of clinical studies specific for pancreas cancer that allow only PDAC patients versus any exocrine pancreatic cancer patient are depicted.